NCT00257972

Brief Summary

The purpose of this research study is to compare the efficacy of aripiprazole with placebo in combination with lithium or valproate monotherapy, in the treatment of bipolar I patients with manic or mixed episodes.

Trial Health

98
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
400

participants targeted

Target at P50-P75 for phase_3

Timeline
Completed

Started Oct 2004

Typical duration for phase_3

Geographic Reach
16 countries

85 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2004

Completed
1.1 years until next milestone

First Submitted

Initial submission to the registry

November 23, 2005

Completed
1 day until next milestone

First Posted

Study publicly available on registry

November 24, 2005

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2007

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2007

Completed
Last Updated

November 8, 2013

Status Verified

May 1, 2008

Enrollment Period

3.2 years

First QC Date

November 23, 2005

Last Update Submit

November 7, 2013

Conditions

Keywords

Bipolar Mania

Outcome Measures

Primary Outcomes (1)

  • Change from baseline to endpoint in a mania rating scale

Secondary Outcomes (1)

  • Response rate and Clinical Global Impression Scale at endpoint

Interventions

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Clinical diagnosis of bipolar I disorder, manic or mixed episode

You may not qualify if:

  • First manic or mixed episode
  • Allergic, intolerant, or unresponsive to lithium and valproate or to aripiprazole
  • Participation in a previous clinical trial within the past month or ever participated in a trial with aripiprazole

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (90)

Local Institution

Little Rock, Arkansas, United States

Location

Local Institution

Riverside, California, United States

Location

Local Institution

Deerfield Beach, Florida, United States

Location

Local Institution

Jacksonville, Florida, United States

Location

Local Institution

Maitland, Florida, United States

Location

Local Institution

Hoffman Estates, Illinois, United States

Location

Local Institution

Oak Brook, Illinois, United States

Location

Local Institution

Newton, Kansas, United States

Location

Local Institution

Newton, Massachusetts, United States

Location

Local Institution

New York, New York, United States

Location

Local Institution

Staten Island, New York, United States

Location

Local Institution

Raleigh, North Carolina, United States

Location

Local Institution

Dayton, Ohio, United States

Location

Local Institution

Media, Pennsylvania, United States

Location

Local Institution

Norristown, Pennsylvania, United States

Location

Local Institution

Philadelphia, Pennsylvania, United States

Location

Local Institution

Columbia, South Carolina, United States

Location

Local Institution

Memphis, Tennessee, United States

Location

Local Institution

Austin, Texas, United States

Location

Local Institution

Bellevue, Washington, United States

Location

Local Institution

Epping, Victoria, Australia

Location

Local Institution

Rousse, Bulgaria

Location

Local Institution

Sofia, Bulgaria

Location

Local Institution

Varna, Bulgaria

Location

Local Institution

Brno-Bohunice, Czechia

Location

Local Institution

Hradec Králové, Czechia

Location

Local Institution

Opava, Czechia

Location

Local Institution

Prague, Czechia

Location

Local Institution

Pärnu, Estonia

Location

Local Institution

Tallinn, Estonia

Location

Local Institution

Tartu, Estonia

Location

Local Institution

Viljandi Maakond, Estonia

Location

Local Institution

Voru Maakond, Estonia

Location

Local Institution

Bordeaux, France

Location

Local Institution

Dole, France

Location

Local Institution

Grenoble, France

Location

Local Institution

Jonzac, France

Location

Local Institution

La Rochelle, France

Location

Local Institution

Limoges, France

Location

Local Institution

Marseille, France

Location

Local Institution

Nîmes, France

Location

Local Institution

Pessac, France

Location

Local Institution

Rennes, France

Location

Local Institution

Berlin, Germany

Location

Local Institution

Jena, Germany

Location

Local Institution

Magdeburg, Germany

Location

Local Institution

Meunchen, Germany

Location

Local Institution

Westersted, Germany

Location

Local Institution

Budapest, Hungary

Location

Local Institution

Gyula, Hungary

Location

Local Institution

Kecskemét, Hungary

Location

Local Institution

Nagykálló, Hungary

Location

Local Institution

Bassano del Grappa, Italy

Location

Local Institution

Cagliari, Italy

Location

Local Institution

Florence, Italy

Location

Local Institution

Pisa, Italy

Location

Local Institution

Roma, Italy

Location

Local Institution

Sassari, Italy

Location

Local Institution

Trieste, Italy

Location

Local Institution

Voghera -Pavia, Italy

Location

Local Institution

Retranchement, Netherlands

Location

Local Institution

Zaandam, Netherlands

Location

Local Institution

Choroszcz, Poland

Location

Local Institution

Kościan, Poland

Location

Local Institution

Krakow, Poland

Location

Local Institution

Poznan, Poland

Location

Local Institution

Torun, Poland

Location

Local Institution

Tuszyn, Poland

Location

Local Institution

Lisbon, Portugal

Location

Local Institution

Leningrad Region, Russia

Location

Local Institution

Moscow, Russia

Location

Local Institution

Saint Petersburg, Russia

Location

Local Institution

Smolensk, Russia

Location

Local Institution

Port Elizabeth, Eastern Cape, South Africa

Location

Local Institution

Westdene, Free State, South Africa

Location

Local Institution

Pretoria, Gauteng, South Africa

Location

Local Institution

Vereeniging, Gauteng, South Africa

Location

Local Institution

Welkom, Gauteng, South Africa

Location

Local Institution

Durban, KwaZulu-Natal, South Africa

Location

Local Institution

Observatory, Western Cape, South Africa

Location

Local Institution

Barcelona, Spain

Location

Local Institution

Madrid, Spain

Location

Local Institution

Valencia, Spain

Location

Local Institution

Vitoria-Gasteiz, Spain

Location

Local Institution

Herisau, Switzerland

Location

Local Institution

Glasgow, Dumbartonshire, United Kingdom

Location

Local Institution

London, Greater London, United Kingdom

Location

Local Institution

Burnley, Lancashire, United Kingdom

Location

Local Institution

South Wales, Mid Glamorgan, United Kingdom

Location

Local Institution

Surbiton, Middlesex, United Kingdom

Location

Related Publications (2)

  • Vieta E, T'joen C, McQuade RD, Carson WH Jr, Marcus RN, Sanchez R, Owen R, Nameche L. Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate/lithium monotherapy: a placebo-controlled study. Am J Psychiatry. 2008 Oct;165(10):1316-25. doi: 10.1176/appi.ajp.2008.07101560. Epub 2008 Apr 1.

    PMID: 18381903BACKGROUND
  • Vieta E, Owen R, Baudelet C, McQuade RD, Sanchez R, Marcus RN. Assessment of safety, tolerability and effectiveness of adjunctive aripiprazole to lithium/valproate in bipolar mania: a 46-week, open-label extension following a 6-week double-blind study. Curr Med Res Opin. 2010 Jun;26(6):1485-96. doi: 10.1185/03007991003779380.

MeSH Terms

Conditions

Bipolar Disorder

Interventions

Aripiprazole

Condition Hierarchy (Ancestors)

Bipolar and Related DisordersMood DisordersMental Disorders

Intervention Hierarchy (Ancestors)

PiperazinesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsQuinolonesQuinolinesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-Ring

Study Officials

  • Bristol-Myers Squibb

    Bristol-Myers Squibb

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
DOUBLE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

November 23, 2005

First Posted

November 24, 2005

Study Start

October 1, 2004

Primary Completion

December 1, 2007

Study Completion

December 1, 2007

Last Updated

November 8, 2013

Record last verified: 2008-05

Locations